In October, hybrid schemes received net inflows in excess of Rs 10,000 crore, taking the total inflows in such schemes in FY22 to Rs 79,431 crore
The success of the IPO is seen as a precursor for more big-ticket public floats to come in the next year
The gain was underpinned by the stock's inclusion in the MSCI Standard Index and strong top-line performance in the September quarter
Technical picks from Osho Krishan, senior manager - equity research, Anand Rathi Shares & Stock Brokers
Shares of Orchid Pharma hit 10 per cent lower limit to end at Rs 1,188 on Thursday
Unsustainable debt levels and uncertain business outlook is a common thread among companies
The stock was down 12% to Rs 120 on Friday, its lowest level since May 13, 2014.